NEFL and myeloid sarcoma: Thus, NfL levels alone are not enough to be used as a diagnostic tool and the utility in NfL as a biomarker for MS is suggested after a confirmed diagnosis and clinical evaluation to rule out contributions from age and other potentially confounding comorbidities [53].